Search Results 1131-1140 of 18226 for Topical

1. AMG 181 Phase 2 Study in Subjects with Moderate to Severe Ulcerative Colitis - Mayo Clinic

   Use of topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to baseline; Use of intravenous or ...

2. Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides - Mayo Clinic

   Topical steroid creams for symptomatic relief for patients in Cohort C (TMF) are exceptions to this rule. Also, the use of physiologic doses of ...

3. A Study to Evaluate AFPᶜ³³²T in Advanced HCC - Mayo Clinic

   NOTE: Use of inhaled or topical steroids is not exclusionary. Sorafenib/Regorafenib/Lenvatinib within 1 week;; Cabozantinib within 2 weeks;; Duration of ...

4. Publications - Nessa Aghazadeh Mohandesi, M.D. - Mayo Clinic

   2023 Jul; 62(7):938-945. Epub 2023 Mar 08. View PubMed; Sadeghi S, Mohandesi NA. Efficacy and safety of topical JAK inhibitors in the treatment of atopic ...

5. Progel Vascular Sealant - Clinical Trials

   Following this injection, subject has a leaking site where a topical sealant/hemostatic agent may be used to control bleeding. Exclusion Criteria: Subject ...

6. Phase 2b Study of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis - Mayo Clinic

   Inhaled and topical corticosteroids are permitted. Refer to Appendix C for a corticosteroid dose conversion table. Women of childbearing potential (WOCBP) ...

7. A Study to Test Nivolumab with Usual Chemotherapy Treatment or Usual Chemotherapy Treatment Alone to Treat Recurrent or Metastatic Nasopharyngeal Cancer - Mayo Clinic

   Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

8. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

   Participant must agree to daily use (and through follow-up) to one of the non-prescription topical antiseptics on their HS lesions such as: chlorhexidine ...

9. Polymyxin b and trimethoprim (ophthalmic route) - Side effects & dosage - Mayo Clinic

   Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding. Drug Interactions. Although certain medicines ...

10. Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer - Mayo Clinic

    Chemotherapy ≤ 6 months prior to randomization (Note: topical chemotherapy will be assessed on a case-by-case basis); Pregnant women; Nursing women; Men or ...